

PACT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

Date of mailing (day/month/year) 24 July 2001 (24.07.01)	
International application No. PCT/SG99/00098	Applicant's or agent's file reference GM/MC/R33-77
International filing date (day/month/year) 04 October 1999 (04.10.99)	Priority date (day/month/year) 05 July 1999 (05.07.99)
Applicant LI, Sam, Fong, Yau et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 16 January 2001 (16.01.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Zakaria EL KHODARY

Telephone No.: (41-22) 338.83.38

14
REC'D 28 SEP 2001

WIPO PCT

Applicant's or agent's file reference GM/MC/R33-77	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/SG99/00098	International Filing Date (<i>day/month/year</i>) 4 October 1999	Priority Date (<i>day/month/year</i>) 5 July 1999
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ G01N 33/543, 29/02		
Applicant INSTITUTE OF MOLECULAR AGROBIOLOGY et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.																								
2.	<p>This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheet(s).</p>																								
3.	<p>This report contains indications relating to the following items:</p> <table border="0"> <tr> <td>I</td> <td><input checked="" type="checkbox"/></td> <td>Basis of the report</td> </tr> <tr> <td>II</td> <td><input type="checkbox"/></td> <td>Priority</td> </tr> <tr> <td>III</td> <td><input type="checkbox"/></td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td>IV</td> <td><input type="checkbox"/></td> <td>Lack of unity of invention</td> </tr> <tr> <td>V</td> <td><input checked="" type="checkbox"/></td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td>VI</td> <td><input type="checkbox"/></td> <td>Certain documents cited</td> </tr> <tr> <td>VII</td> <td><input type="checkbox"/></td> <td>Certain defects in the international application</td> </tr> <tr> <td>VIII</td> <td><input checked="" type="checkbox"/></td> <td>Certain observations on the international application</td> </tr> </table>	I	<input checked="" type="checkbox"/>	Basis of the report	II	<input type="checkbox"/>	Priority	III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	IV	<input type="checkbox"/>	Lack of unity of invention	V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	VI	<input type="checkbox"/>	Certain documents cited	VII	<input type="checkbox"/>	Certain defects in the international application	VIII	<input checked="" type="checkbox"/>	Certain observations on the international application
I	<input checked="" type="checkbox"/>	Basis of the report																							
II	<input type="checkbox"/>	Priority																							
III	<input type="checkbox"/>	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
IV	<input type="checkbox"/>	Lack of unity of invention																							
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
VI	<input type="checkbox"/>	Certain documents cited																							
VII	<input type="checkbox"/>	Certain defects in the international application																							
VIII	<input checked="" type="checkbox"/>	Certain observations on the international application																							

Date of submission of the demand 16 January 2001	Date of completion of the report 19 September 2001
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer J. BODEGRAVEN Telephone No. (02) 6283 2281

I. Basis of the report

1. With regard to the **elements** of the international application:*
- ☒ the international application as originally filed.
- ☒ the description, pages **1-30**, as originally filed,
pages , filed with the demand,
pages , received on with the letter of
- ☒ the claims, pages **31-33**, as originally filed,
pages , as amended (together with any statement) under Article 19,
pages , filed with the demand,
pages , received on with the letter of
- ☒ the drawings, pages **1/13-13/13**, as originally filed,
pages , filed with the demand,
pages , received on with the letter of
- ☒ the sequence listing part of the description:
pages **1-4**, as originally filed
pages , filed with the demand
pages , received on with the letter of
2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:
- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished
4. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 2, 9, 10, 20-25, 27-29	YES
	Claims 1, 3-8, 11-19, 26	NO
Inventive step (IS)	Claims 9, 10, 22, 23, 25, 28, 29	YES
	Claims 1-8, 11-21, 24, 26-27	NO
Industrial applicability (IA)	Claims 1-29	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

The following documents (D), which are cited in the search report, are referred to in the present report.

D1: US Patent 4,735,906 (BASTIAANS);

D2: EP 0 781 999 (DADE BEHRING MARBURG GMBH);

D3: WO 97/04314 (YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM);

D4: Journal of Food Science, Vol. 62 (5) 1997, JIANMING YE et al.,

D5: WO 98/40739 (YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM).

NOVELTY (PCT Article 33(2))

D1 discloses a sensor and method for performing immunoassays using a piezoelectric crystal on which a specific antibody or antigen is bound. The resonant frequency is measured both before the crystal with bound antibody or antigen is exposed to a test solution and after the crystal has been exposed to the test solution. The sensor can be used to perform an immunoassay involving antibodies, viruses, cells, bacteria, drugs, toxins, and complexed metal ions. An antigen or antibody is chemically bonded to the surface of a piezoelectric quartz crystal. Electrodes are provided on the crystal. An oscillator circuit is attached which can include a Universal Counter.

This disclosure deprives the subject matter of claims 1, 3, 4, 7, 8, 11, 13, 19 and 26 of novelty.

D2 discloses a piezoelectric sensor for use in diagnostic and analytic processes in particular for the immunochemical detection of diagnostically relevant specific binding partners. A gold coated piezoelectric crystal integrated into an electronic circuit is coated with a binding partner which may be an antibody, lectin or antigen. Following coating the sensor is washed and may be blocked with BSA or inactivated POD in order to prevent non-specific binding. The coated sensor is incubated with the sample, for example, by dipping into the sample or by application of the sample onto the sensor. The amount of analyte bound can be determined by a change in the resonant frequency. The sensor may be regenerated by washing with a reducing or oxidising agent such as sodium borohydride or tetrabutylammonium hydroxide.

This disclosure deprives the subject matter of claims 1, 4, 7, 8, 11, 12, 14, 16-19 and 26 of novelty.

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of Box V

D3 discloses a probe comprising a piezoelectric crystal with electrodes and metal plates which may be the same as the electrodes. A first member of a recognition pair is immobilized on the probe and the probe is exposed to a test solution for binding of a second member with the resonance frequency being measured both before and after binding (see, in particular, page 8). The analyte to be detected may be suspended or dissolved in a gas. The metal plates (electrodes) may be made of gold, platinum, silver or copper. The immobilized member may be immobilized by means of a linking group. The probe may be re-used by exposure of the members of the binding pair to light of an appropriate wavelength or by mild thermal treatment.

This citation deprives the subject matter of claims 1, 3, 5-8, 11, 12, 19 and 26 of novelty.

D4 discloses a piezoelectric biosensor for the detection of *Salmonella typhimurium*. Anti-*S. typhimurium* antibody is immobilized onto the gold electrode coated quartz crystal surface. Unreacted sites are blocked with BSA. The coated crystal is dipped into the test sample.

This citation deprives the subject matter of claims 1, 3, 5-7, 11, 16-19 and 26 of novelty.

D5 discloses a piezoelectric crystal provided on its surface with a metal plate (which can also function as the electrode) with a specific binding entity immobilized thereon. The biosensor is used to determine the presence of cells (such as yeast, bacteria as well as viral particles) in a liquid medium such as urine, blood or mucous. The specific binding entity may be antibody or lectin. Blocking agents (BSA, animal sera, gelatin, casein, polymers) may be used. The antibody may be immobilized via a linking group.

This citation deprives the subject matter of claims 1, 3-7, 11-19 and 26 of novelty.

INVENTIVE STEP (PCT Article 33(3))

Claims 1, 3-8, 11-19 and 26 do not satisfy the requirements of Article 33(3) for the same or similar reasons as given above.

D1 discloses a quartz ST-cut "surface acoustic wave device". However the skilled addressee is directed to "other types of piezoelectric materials" which can also be used for the crystal. An AT-cut quartz crystal would be a suitable alternative for an ST-cut quartz crystal. Thus claim 5 does not satisfy the requirements of Article 33(3). While the citation does not expressly disclose whether the immobilization is performed via dipping or dropping the antigen or antibody onto the sensor, it is probable that the antigen or antibody is immobilized by either means. As the applicant has not demonstrated that "dipping" offers any particular advantage over and above other application methods, claim 12 cannot be considered to satisfy the requirements of Article 33(3). Claim 24 does not satisfy the requirements of Article 33(3) as D1 teaches the skilled addressee that the sensor can be reused by disrupting the antigen-antibody complex through washing the sensor with "any solution which disrupts the antigen-antibody complex" such as a high ionic strength solution.

D2 fails to disclose which type of piezoelectric crystal was used. However, the citation includes a reference to prior art (including D1) with regard to the crystal. Therefore, claim 5 (as noted above) cannot be considered to satisfy the requirements of Article 33(3). Claim 6 does not satisfy the requirements of Article 33(3) as the use of silver or gold electrodes with a piezoelectric crystal as a biosensor would be obvious to a skilled addressee familiar with this art.

D3 does not disclose an "oscillator circuit or "universal counter" as such. However the selection of these integers would have been obvious to a skilled addressee having prior knowledge of piezoelectric crystals and their use as biosensors.

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of BOX V (Inventive Step):

It would be obvious to the skilled addressee in this case that the detection of resonance frequency would be made by such means as an analyzer or counter. Thus claims 7 and 8 do not satisfy the requirements of Article 33(3).

D4 also does not explicitly disclose a 'universal counter'. However, a "frequency counter" is disclosed. As noted above, a skilled addressee would have found a 'universal counter' an obvious selection for the measurement of resonant frequency. Thus, claim 8 does not satisfy the requirements of Article 33(3).

D5 also does not disclose a "universal counter" as in claim 8. The claim does not satisfy the requirements of Article 33(3) for the reasons as given above.

Further Observations on Article 33(3) Inventive Step:

Claim 13 refers to the dilution of biological sample before contacting with the piezoelectric sensor. An inventive step cannot be acknowledged as this is routine practice in the art of assaying biological samples. Claim 13 does not satisfy the requirements of Article 33(3).

Claims 12, 18 and 26 refer to the application of sample or blocking agent by a "dip" or "drop" technique. The dipping or dropping of a sample or buffer to establish contact with a biosensor cannot be considered to demonstrate an inventive step as it would be obvious for a skilled addressee to use either method of application to apply a sample to a substrate.

Claim 21 refers a piezoelectric crystal which was previously used in a test which was negative for the infectious agent. It would be obvious for a skilled addressee to reuse a biosensor which had previously recorded a negative response either directly or following a washing step. Thus claim 21 does not satisfy the requirements of Article 33(3).

Claims 2, 10 and 27 refer to a "recombinant" antigen or antibody. The generation of antigens or antibodies using recombinant technologies is well known and these techniques are routinely used. The mere choice of any antigen or antibody which has been recombinantly produced therefore cannot be considered to demonstrate an inventive step.

Claim 20 does not satisfy the requirements of Article 33(3). The measurement of a "cut-off threshold" as a "mean value of negative controls plus three times the standard deviation" is considered to be a mere workshop variation of a standard means of estimating the "negative control" for an immunoassay. A skilled addressee would have found it obvious to take the average reading for a number of negative controls and used this together with the standard deviation to establish a "cut off threshold".

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

1. There is no support for claims 9 and 10 in the description with regard to the antigen being a "transmembrane envelope protein".
2. There is no support in the description for claim 19 with regard to the contacting of a biological specimen in "a vapour phase".

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No

PCT/SG 99/00098

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/543 G01N29/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YE J ET AL: "PIEZOELECTRIC BIOSENSOR FOR DETECTION OF SALMONELLA TYPHIMURIUM" JOURNAL OF FOOD SCIENCE, US, INSTITUTE OF FOOD TECHNOLOGISTS. CHICAGO, vol. 62, no. 5, 1 January 1997 (1997-01-01), pages 1067-1071, XP002072264 ISSN: 0022-1147	1,3-8, 11, 13-20,27
A	the whole document	28,29
X	US 4 735 906 A (BASTIAANS GLENN J ET AL) 5 April 1988 (1988-04-05) cited in the application column 6, line 17 - line 30; claim 1; example 1	1-8, 12-20,27
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

15 February 2000

Date of mailing of the international search report

22/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gundlach, B

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/SG 99/00098

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 40739 A (YISSUM RES DEV CO ; LEVI SHLOMO (IL); BEN DOV IDDO (IL); WILLNER IT) 17 September 1998 (1998-09-17) page 5, line 1 - line 19	1,3-8, 11, 13-20,27
X	WO 97 04314 A (YISSUM RES DEV CO ; WILLNER ITAMAR (IL); LEVI SHLOMO (IL); COHEN YA) 6 February 1997 (1997-02-06)	1-3,5-8, 11
A	claim 1; figure 1	24,25
A	EP 0 781 999 A (BEHRINGWERKE AG) 2 July 1997 (1997-07-02) claims 1-9	24,25

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Patent Application No

PCT/SG 99/00098

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4735906 A	05-04-1988	NONE	
WO 9840739 A	17-09-1998	AU 6634298 A EP 0970374 A	29-09-1998 12-01-2000
WO 9704314 A	06-02-1997	AU 6317896 A EP 0843816 A JP 11510247 T	18-02-1997 27-05-1998 07-09-1999
EP 0781999 A	02-07-1997	DE 19548376 A AU 7549896 A CA 2193318 A JP 9189701 A	03-07-1997 03-07-1997 28-06-1997 22-07-1997

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02858 A1

(51) International Patent Classification⁷: G01N 33/543, 29/02

(21) International Application Number: PCT/SG99/00098

(22) International Filing Date: 4 October 1999 (04.10.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9903147-8 5 July 1999 (05.07.1999) SG

(71) Applicants (for all designated States except US): INSTITUTE OF MOLECULAR AGROBIOLOGY [SG/SG]; The National University of Singapore, 1 Research Link, Singapore 117604 (SG). INSTITUTE OF MATERIALS RESEARCH AND ENGINEERING [SG/SG]; The National University of Singapore, S7 Level 3, Singapore 119260 (SG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): Li, Sam, Fong,

Yau [SG/SG]; 5 Pine Grove, #07-03, Singapore 597591 (SG). SU, Xiaodi [CN/SG]; Block 41, #03-347, Teban Gardens Road, Singapore 600041 (SG). KWANG, Jimmy [US/SG]; 87 Pasir Panjang Hill, #02-09 Kentview Park, Singapore 118892 (SG). LOW, Sharon [SG/SG]; #01-04, 17C Nassim Park, Nassim Road, Singapore 258394 (SG). LIU, Wei [CN/SG]; Block 11, #06-110, Red Hill Close, Singapore 151011 (SG).


(74) Agent: ELLA CHEONG & G. MIRANDAH; P.O. Box 0931, Raffles City, Singapore 911732 (SG).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent

[Continued on next page]

(54) Title: IMMUNO-DIAGNOSTIC TEST METHOD FOR VETERINARY DISEASE



(57) Abstract: The present invention provides a method for the qualitative detection of viral or bacterial antibodies from animal body fluid, and an apparatus for performing the same. The apparatus according to one aspect includes a piezoelectric crystal, which is operated by an oscillation circuit, and the resonant frequency is measured by using a universal counter. According to another aspect, the recombinant viral or bacterial protein is immobilized on the surface of the said Pz crystal and acts as an antigen. In one embodiment, the presence or absence of viral or bacterial specific antibody may be determined using the fabricated Pz sensor by monitoring the frequency change signal. In another embodiment, the present method is proved to be inexpensive, simple and rapid.



(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *With international search report.*

TITLE OF THE INVENTION

IMMUNO-DIAGNOSTIC TEST METHOD FOR VETERINARY DISEASE

FIELD OF THE INVENTION

5 The present invention is related to an apparatus and method for performing immunodiagnostic testing for veterinary disease. In particular it is related to the detection of the presence of viral or bacterial antigens by measuring specific antibodies in animal body fluid in which viral or bacterial proteins serve as the antigens. Highly specific antigen-antibody interactions are utilized to bind antibodies onto a piezoelectric crystal transducer for detection.

10

BACKGROUND OF THE INVENTION

 The publications and other materials used herein to illuminate the background of the invention or provide additional details respecting the practice, are incorporated by reference, and for convenience are respectively grouped in the appended List of References.

15

 In the veterinary diagnostic laboratory, the most common need for diagnostic testing is to diagnose disease, which usually involves testing for the presence of viral or bacterial antigens, or antibodies to them. Traditional methodologies practicing this art such as viral isolation, virus neutralization, plate agglutination, hemagglutination inhibition, immunodiffusion, classical microbiological culture techniques, high-pressure liquid chromatography, and thin layer chromatography, are very slow and costly, requiring days or even weeks for confirmation results. To accelerate and simplify current immunoassay techniques, the use of highly specific antigen-antibody reaction is becoming increasingly important. Techniques such as radioimmunoassay (RIA), immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), and Western immunoblot (WB) have shown considerable degrees of success and have are used in veterinary diagnostic laboratory nowadays.

25

 Most of the said immunoassays are conducted in laboratories that use relatively expensive equipment and skilled personnel. Most tests involve manipulation and multiple procedures. For example, a traditional solid phase sandwich immunoassay for viral or bacterial antigen/antibody detection comprises the following procedures: (a) Immobilizing antibody/antigen peptide to a solid support, (b) Reacting immobilized antibody/antigen from step (a) with samples suspected of containing antigen/antibody against coated antibody/antigen to form an immunocomplex, (c) Washing the immunocomplex of step (b) with washing solution comprising detergents to remove

30

unbound antigen/antibody, (d) Reacting the immunocomplex with an enzyme or radiolabeled second antibodies to form a sandwich complex, (e) Separating the sandwich complex from unbound labeled second antibodies by washing, (f) Reacting the sandwich complex with a compound able to act as a substrate for the enzyme or radiolabel so that the catalytic reaction can be colorimetrically monitored.

The use of radioisotope- or enzyme-labeled second antibody in the assay procedures presents problems of waste handling and increases the cost of the assay. The multiple reaction processes and long incubation time require 8-10 hours from initial sample processing to delivery of final results. The requirements for refrigerated storage of reagents, expensive equipment, and reliable power supply make the assay techniques difficult to perform outside a well-equipped laboratory or under field conditions.

Attempts to overcome the limitations imposed by these requirements have led to the development of a variety of rapid immunoassay methods. For example, dot enzyme immunoassay (DEI), dot immuno-binding assay (DIA), and various particle agglutination tests are developed for the routine laboratory diagnosis for viral/bacterial serum antibodies. In these assays, antigens are dotted onto nitrocellulose strips or sheets, and sera are applied on absorbent paper strips. Antigen/antibody complexes are detected with enzyme-conjugated antiglobulin and development of a colored, insoluble substrate product. This test allows processing the serum detection within a relatively short time (1-5 h). Although these assays have improved the utility outside the laboratory environment, their usefulness is still somewhat limited by the potential temperature sensitivity inherent in enzyme-linked systems, and by the need for the specific anti-immunoglobulin reagents (Heberling and Kalter, 1986).

Other attempts have also been made to simplify and modify the traditional immunoassay. U.S. Patent No. 5,695,928 disclosed an immunoassay capable of the rapid detection of a variety of test substances in a test sample. The feature of the invention is that extraction and isolation of the test substance occur simultaneously with the formation of the primary antigen-test substance complex. The primary antigen-test substance complex is then captured in a solid phase format having a plurality of interstitial spaces which facilitate rapid and efficient detection.

U.S. Patent No. 5,630,924 disclosed compositions, methods, and apparatus for performing ultrafast binding assays by capillary electrophoresis or other electroseparation techniques.

U.S. Patent No. 5,565,365 disclosed a system for assaying a fluid sample by detection of radiation emitted from a ligand/conjugate complex formed on a plurality of beads dimensioned within a specified range of diameters. The beads are disposed as a porous mass in conduit adjacent to a fluid-porous screen having pores of lesser diameter than the range of diameters of the beads. A plurality of paramagnetic particles is suspended across the conduit by a magnetic field of sufficient intensity to array the paramagnetic particles as the fluid-porous screen.

U.S. Patent No. 5,554,340 disclosed an assay system for a fluid sample, typically employing a fluorescent tag. The system comprises a lens capable of focussing both excitation and fluorescent radiation, a fluid-flow conducting conduit being provided in the lens extending transversely of the optical axis of and through the focal region of the latter. One or more mechanical screens are disposed adjacent to the focal region in the conduit to arrest passage of beads as a function of bead diameter. The beads, precoated with at least a moiety of a ligand/conjugate complex, e.g. a specific-binding ligand, are preferably substantially transparent to both the excitation and fluorescent radiation.

U.S. Patent No. 5,212,065 disclosed a rapid immunoassay device comprising a single porous membrane that serves as both a reagent support and a spent reagent reservoir. The immunoassay device directs the flow of sample and reagents within the device in a manner that eliminates both lateral diffusion and backflow of reagents without the necessity of additional external means.

U.S. Patent No. 5,236,824 disclosed an *in-situ* laser magnetic immunoassay (LMIA) method which eliminated the step of B/F separation generally required in the labeling method of immunoassays. The laser magnetic immunoassay permits a quantitative determination of a target immunological substance, for example, antigens, antibodies, lymphocytes, viruses, tumor cells and infected cells, in an analyte solution containing both bound and free species. A transitory increase in the magnetophoretic scattering of a laser beam is observed when the analyte solution contains magnetic-labeled, bound target analyte, while no such increase is observed in a control test solution containing only the relevant reagents. A magnetophoretic LMIA apparatus is provided which includes a magnetic gradient-generating device, which forms an integral part of the *in-situ* LMIA.

An alternative method to perform the assay of antigen or antibody is the use of an antigen/antibody-based biosensor. Biosensors offer the advantages of inexpensive equipment that

can be taken out of the laboratory to where the sample may be added by unskilled personnel; the result would ideally be available rapidly. Immunosensors can detect the antigen/antibody concentration either by direct competitive and displacement reactions similar to the immunoassays or by direct changes in transducer output (Karube and Suzuki, 1986). For the former type of system, the range of sensor transduction includes optical, amperometric, and radiochemical mechanisms. Similar to the traditional immunoassay, these detection methods generally require the use of labeled receptors and several preparative steps to the overall assay. An alternative sensor system, which can monitor the antigen-antibody interaction by direct changes in transducer output, is a mass-detection sensor. This sensor system can monitor an antigen/antibody reaction directly by the detection of mass change. The assay concept and procedure are simple and any use of potentially hazardous materials is eliminated. An example for this type of system is the piezoelectric (Pz) crystal device. With this system, assays both in gas phase and in solution are possible.

A Pz crystal device consists of a quartz crystal wafer sandwiched between two metal electrodes. The electrodes provide means of connecting the device to an external oscillator circuit that drives the quartz crystal at its resonant frequency. This frequency is dependent on the mass of the crystal, as well as the mass of any layers confined to the electrode areas of the crystal. Changes in mass on the surface of the electrode thus change the frequency of the Quartz Crystal Microbalance (QCM) device. The use of a piezoelectric (Pz) oscillator as a potential biomedical sensor is based on the relationship of the frequency change and the mass loading on the surface of the crystal described by the following equation:

$$\Delta F = - 2 F_0^2 \Delta m / A (\rho_q \mu_q)^{1/2}$$

where ΔF is the measured frequency shift, F_0 is the fundamental frequency of the Pz crystal, A is the area coated, Δm is the mass change due to surface deposition, ρ_q is the density of the quartz crystal (2.648 g cm^{-3}) and μ_q is the shear modulus ($2.947 \times 10^{11} \text{ g cm s}^{-1} \text{ s}^{-2}$ for AT-cut quartz crystals). The mass sensitivity can be described as:

$$S = 2 F_0^2 / (\rho_q \mu_q)^{1/2}$$

For a 10 MHz piezoelectric crystal, mass sensitivity $S = 0.227 \text{ Hz ng}^{-1} \text{ cm}^2$, predicts that 4.4 ng/cm^2 of adsorption leads to a frequency change of about 1 Hz.

Pz crystal based immunosensor technology is the combination of the use of a Pz device, protein immobilization, and antigen-antibody interaction. The key to constructing a Pz

immunosensor is the surface modification by which a sensitive antigen or antibody receptor layer is created so that the target analyte from the sample can be adsorbed selectively.

Methods of protein immobilization used in the fabrication of a biosensor include physical adsorption onto a support (metal or polymer), entrapment within a membrane, and covalent binding to the support (Williams and Blanch, 1994). All methods have distinct advantages, for example, a physical method is experimentally simple and regarded as a mild coupling method that preserves protein activity. However, in certain situations, it can be somewhat reversible and does not provide as high a surface loading of protein as covalent coupling. In covalent immobilization methods, chemical bonds are made between the surface and the attached species. Although generally harsher than other immobilization schemes, covalent binding provides the highest irreversible surface loading which is beneficial for the sensitivities of the sensor. Moreover, covalently bound proteins are relatively resistant to the operational conditions. In general, the preliminary requirements for the protein immobilization are the maintenance of activity, a sufficient amount of binding, and strong adhesion of the coated protein on the coated support. Different immobilization methods provide different sensor performance and are suitable for different types of proteins to be immobilized.

The first use of an antigen as a Pz crystal coating was demonstrated by Shons et al. (1972) and was based on adsorption of antigen on a low energy plastic coating, nyerbar C (30%) solution in 1-3 di(trifluoromethyl) benzene, providing a layer capable of forming hydrophobic bonds with proteins. After coating with antigen, the crystal was exposed to an unknown amount of antibody solution. The immunoreaction between antibody and antigen-coated crystal resulted in the immunobinding of the antibody. Frequency shift caused by mass loading is proportional to the concentration of the specific antibody in solution.

U.S. Patent No. 4,242,096 disclosed an indirect immunoassay for detecting an antigen in a liquid sample, in which an antigen was covalently coated onto a crystal having a polymer monolayer such as poly(2-hydroxy-3-dimethylamino-1,4-butane). The using of a polymer priming surface followed by adsorption of the antigen was also disclosed in U.S. Patent Nos. 4,236,893 and 4,314,821, among others. U.S. Patent No. 4,735,906 disclosed a method for protein immobilization using a crystal with a surface modified to form a layer of siloxane polymer, which in turn immobilizes protein through amide linkages. Bastiaans (U.S. Patent No. 4,735,906) disclosed a method for an immunoassay using ST-cut piezoelectric SAW devices in

a solution phase. The surface of the crystal is modified by silane derivative, glycidoxypyltrimethoxysilane (GOPS). Singapore Patent Application No. 9801211-5 (S. F. Y. Li) disclosed the self-assembly immobilization technique by which the performance of a sensor system was greatly improved compared with other immobilization methods.

5 Recombinant technology plays an important role in protein biotechnology, by which large quantities of recombinant proteins can be generated as the products of genetic engineering. The aim of producing recombinant proteins can be grouped into four broad categories (Franks, 1993): 1) To obtain large quantities of a protein; 2) To study site-directed mutant proteins; 3) To produce proteins for biotechnology; 4) To manipulate metabolism *in vivo*. In particular, for
10 example, the development of an enzyme immunoassay requires large quantities of structurally well-defined proteins as immunogen and enzymatic tracer. In recent years, there has been growing interest in the use of viral or bacterial specific antigens, produced by recombinant techniques, as protective immunogens in serological tests. For purposes of this disclosure, a recombinant protein or recombinant antigen is a protein or antigen prepared from an organism
15 or cell or from a descendant of an organism or cell into which a gene for the protein or antigen has been cloned and wherein the recombinant protein can be a fusion protein.

— The present invention combines the Pz transducer together with the recombinant protein based immunoassay to perform diagnoses for viral or bacterial disease in animals. The fabricated Pz crystal sensor can thus monitor antigen-antibody interaction directly by sensing the mass
20 change of the crystal. It has been proved to be helpful in overcoming the limitations of traditional immunoassay methods. The obvious advantages provided by the novel technology are the following: 1) The system has a fundamental low cost and can be performed in a non-equipped lab; 2) The fundamental design and performance are relatively simple; 3) The ease to realize real-time display of the results and rapid on-site testing; and 4) Minimal usage of hazardous material
25 and use of unlabeled reagents which, unlike a conventional labeled immunoassay, is less temperature sensitive and allows for stable storage and shipment at 20-25°C.

Salmonella enteritidis (SE) is a major problem for the poultry industry. In the last ten years SE has been one of the dominant *Salmonella* serotypes isolated from humans with food poisoning in many countries. This phenomenon has been associated with an increase in the
30 numbers of poultry and eggs contaminated with these serotypes. Bacteriological techniques for the isolation of *Salmonella* from clinical and environmental samples are laborious, lengthy, and

expensive. They may not identify all *S. enteritidis*-infected flocks because of the intermittent nature of *Salmonella* extraction and the number of samples that can be processed. However, chickens infected with invasive serotypes like *S. enteritidis* develop a persistent immunoglobulin G response to the infecting organism. Thus, mass serological screening for a flock infected with *S. enteritidis* offers a relatively cheaper and more practical alternative, provided that it gives at least the same performance as bacterial methods. Thorns et al. (1996) established ELISA-based serological tests for *S. enteritidis*. This method is based on the traditional solid phase immunoassay in which a novel fimbrial antigen termed SEF 14 was first described in strains of *S. enteritidis* and pre-coated on the solid phase. Under the typical ELISA procedures SEF14 specific antibodies from chicken sera and egg yolk were detected qualitatively. U.S. Patent No. 4,689,295 disclosed a method of detecting the presence of *Salmonella* in food samples. It includes providing at least one DNA probe which is capable of selectively hybridizing to *Salmonella* DNA to form detectable complexes, contacting the DNA probes with the bacteria in the food sample under conditions which allow the probe to hybridize to *Salmonella* DNA present in the food sample to form hybrid DNA complexes, and detecting the hybrid DNA complexes as an indication of the presence of *Salmonella* in the food sample.

Porcine reproductive and respiratory syndrome (PRRS) is an economically important disease in pigs worldwide. The PRRS virus (PRRSV), a positive-stranded RNA virus belonging to the genus Arterivirus, causes this disease. Current diagnosis for the disease is based on: 1) clinical signs, which are used as characteristic in acute outbreaks, but are not as effective in diagnosing low-grade disease; 2) virus isolation, which is little used as it is time consuming and less reliable; 3) polymerase chain reaction (PCR) testing for PRRS antigen; and 4) serological tests used for herd profiling, which include immunoperoxidase monolayer assay (IPMA), indirect enzyme-linked immunosorbent assay (ELISA), and indirect immunofluorescence assay (IIFA).

IDEXX Laboratories, Inc. of Maine, U.S.A., has a series of antibody diagnostic tests for the detection of alternative virus or bacteria infectious diseases of animal. *Salmonella enteritidis* antibody test kits and PRRS antibody test kits from IDEXX rely on competitive and sandwich enzyme linked immunoassay (ELISA) techniques, respectively. In these specific antibody test kits, antigen-coated plates and all reagents (including enzyme-conjugated antibody, substrate, sample diluent, washing buffer, positive/negative control, etc.) are provided. The test protocol comprises procedures of sample incubation, enzyme conjugated antibody incubation, substrate

incubation, and multi-washing steps. The final signals are measured by spectrophotometer. The whole procedure (from contacting the detected sample to the coated plate) takes 3-5 hours, costs US\$3-5 each test, and a well-equipped laboratory and skilled personnel are needed to perform the assays. Although these assays are proved to be highly accurate, sensitive and specific, the above mentioned limitations make it difficult to perform a large number of on-site screening tests under field conditions.

OBJECTIVE OF THE INVENTION

It is therefore an object of the present invention to provide an apparatus and method for diagnosis of veterinary diseases, which involves the detection of viral or bacterial antigen specific antibodies. It is also an object of the invention to detect viral or bacterial specific antigens.

It is therefore an objective of the present invention to provide a method to fabricate a Pz crystal based sensor by using recombinant protein as receptor material and to perform detection for antigen specific antibodies.

It is another objective of the invention to provide a simplified and shortened method for the detection of *Salmonella enteritidis* and PRRSV infection disease.

SUMMARY OF THE INVENTION

The present invention provides a method for an immunodiagnostic test for veterinary diseases, which involves the detection of the presence of viral or bacterial antigens or antibodies to them. The apparatus according to one aspect includes an immunosensor which uses a Pz crystal as reaction carrier. According to another aspect, the recombinant viral or bacterial antigen is immobilized on the surface of the crystal to work as a sensing receptor. A Pz crystal device can sense a mass change caused by the antigen-antibody interaction on the surface of the crystal.

The *Salmonella enteritidis* (SE) or PRRSV detection method includes fabricating a Pz sensor by covalently or physically immobilizing a recombinant SE or PRRSV protein on the surface of the crystal. The technique adopted is either dip- or drop-coating by which the use of minimal amount of the protein is taken into consideration. After blocking by certain reagents the coated interface is exposed to the specimens to be detected (e.g., chicken serum, egg yolk, pig serum), which are suspected to contain SE or PRRSV antibodies for an appropriate period of

time (from several seconds to several hours). The frequencies of the fabricated crystal before and after incubation with a specimen are measured. The frequency change or absence of a frequency change indicates the presence or absence of the target antibodies. Besides the protein coupling procedure, other technique details including washing buffer, blocking reagent, and the dilution ratio of the detected specimen are disclosed.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic of the Pz crystal sensor system

Figure 2 is a flow diagram showing the procedures for constructing a Pz sensor with a specific sensing material layer on it and procedures for running the samples.

Figure 3 is a diagram of a microcontainer used in the dip coating process.

Figure 4 shows the principle of a Pz sensor for the detection of a target antibody.

Figure 5 shows the frequency change caused by positive and negative controls for detecting *Salmonella enteritidis* antibodies.

Figure 6 shows the frequency change for 35 unknown chicken sera samples tested for *Salmonella enteritidis* antibodies.

Figure 7 shows SE-Pz sensor detection results for 7 previously characterized negative egg yolks and 12 previously characterized positive egg yolks.

Figure 8 shows the relationship between protein binding amount and sensitivity of the fabricated Pz sensor.

Figure 9 is a summary of measurement results for 41 pig sera. Group A is real negative samples, group B is positive controls and group C is unknown samples.

Figure 10 shows the reusability of fabricated PRRSV Pz sensors.

Figure 11A shows the sensitivity of a regenerated PRRSV Pz sensor. Figure 11B shows the sensitivity of a regenerated SE Pz sensor. In both figures ○ is positive control 1 and ● is positive control 2.

Figure 12 shows the regeneration ability of dichromic acid solution (●) and hot Piranha (○) with a used SE Pz sensor with a thiol compound treated surface.

Figure 13 shows the regeneration ability of dichromic acid solution to thiol compound (●) and γ -APTES (○) treated crystals.

DETAILED DESCRIPTION OF THE INVENTION

The detailed procedures of a Pz crystal device as a sensor system can be understood by reference to the drawings.

The conventional Pz crystal device design (see Figure 1) has a metal electrode 20 deposited on each of the two sides of the wafer 22. These two electrodes are connected to an oscillation circuit 24 and a frequency counter 26 for generating and detecting resonant frequencies, respectively. Standard methods such as that described by Shons et al. (1972), use a thin disk of AT-cut quartz crystal containing two electrodes on the double sides. Due to the piezoelectric properties and crystalline orientation of the quartz, the application of a voltage between these electrodes results in a shear deformation of the crystal. These electrodes are used to induce an oscillating electric field perpendicular to the surface of the quartz wafer. The oscillating field produces a mechanical oscillation, a standing wave, in the bulk of a quartz wafer. A resonance oscillation is achieved by including the crystal in an oscillation circuit, where the electric and mechanical oscillations are closed to the fundamental frequency of the crystal. The oscillation circuit and the frequency counter (such as HP 5213A from Hewlett Packard, USA) are well known in the art, and are described in detailed by Breckenstein and Shay (1985). The fundamental frequency depends on the thickness of the wafer, its chemical structure, its shape, and its mass, and can be determined by using a universal counter. The most commonly used crystals are 5, 9, or 10 MHz quartz in the form of 10-16 mm disks that are approximately 0.15 mm thick. Metals are often gold, silver, aluminum, or nickel. In the present invention, the crystal is an AT-cut 10 MHz quartz wafer of 14 mm diameter and 0.2 mm thickness. The gold electrode is 5.1 mm diameter and 100 nm thickness. This crystal offers a mass sensitivity of about 0.902 ng/Hz.

To construct a Pz crystal device as an immunosensor system, the procedures include fabrication of the sensor and the detection of the samples. The fabrication of a Pz crystal as a sensor usually involves surface modification by which a specific bioreceptor interface is created. The assay is based on the transformation of a specific interaction into a frequency signal. When exposing the fabricated sensor to samples, the interaction between a coated interface and a detected analyte results in a change of frequency signal, which can be used to quantitatively or qualitatively identify the target analyte directly.

Figure 2 shows the detailed procedures for both constructing a Pz crystal based biosensor and the testing of sample.

First, the crystal, more particularly the surface of the metal electrode, must be cleaned by washing with an appropriate acid, base, and organic solution. To meet with different surface modification procedures, the appropriate washing methods are adopted. For example, to build a thiol compound based self-assembly monolayer, hot Piranha solution is usually the first method to be considered. Hot Piranha solution can get rid of any oxidizing agent, and as a result a hydrophilic gold surface can be obtained. An alternate washing procedure, which comprises soaking the surface of the crystal in base and acid alternately, can be used for polymer modification. After soaking in base and acid, rinsing steps with distilled water and organic chemicals are performed. The fundamental frequency of the cleaned crystal can be measured as F_0 under dry condition and atmospheric pressure.

In the present invention, several conventional protein immobilization methods are adopted including direct physical adsorption onto the bare metal electrodes, covalent binding on the silane treated crystal, covalent binding on a thiol compound modified surface, and physical adsorption on a hydrophobic polymer (polystyrene) modified crystal.

The physical adsorption of protein on the bare gold surface is based on the strong and irreversible hydrophobic and thiol-gold interaction (Horisberger and Vauthey, 1984). This method is experimentally simple and it does not require any chemical step to modify the gold surface. The adsorption is achieved by incubation of a hot Piranha solution treated crystal (F_0) directly with the solution containing biomolecules and allows the molecules to be adsorbed to the surface of the crystal over an appropriate period of time. The resonant frequency after incubation with the biomolecule is determined as F_B . $F_0 - F_B$ is related to the amount of biomolecule binding.

Covalent immobilization is also commonly employed. The procedures of covalent binding normally include modification of the crystal by an appropriate first chemical by which a desired functional group can be introduced onto the surface of the crystal, and covalent bonds can be made between the surface and the attached species. The most commonly used activating functional groups include primary amines, thiols, hydroxyls, and carboxylic acids. For example, polyethylenimine (PEI) or γ -aminopropyltriethoxysilane (γ -APTES) modification provides the crystal surface with an amino group; any thiol compound with a terminal -COOH group can

provide the crystal with a -COOH modified surface. To activate the functional chemical modified surface, a second chemical is sometimes employed as a cross-linking or coupling reagent. Normally the cross-linking or coupling reagents are used to provide additional chemical linkages between the active biomaterial with the modified surface or to activate the modified surface further.

In a traditional immunoassay technique, the most widely used solid phase is the 96-well microtiter plate manufactured from a hydrophobic polymer such as polystyrene (inflexible "rigid" plates) or polyvinyl chloride (PVC, flexible plates). The antigens or antibodies can be attached to the plastic surfaces easily by the hydrophobic interaction between nonpolar protein substructures and the polymer (Crowther, 1995). In Pz sensor fabrication, the binding of protein onto a hydrophobic polymer modified crystal is based on the use of the idea in this reference. This immobilization concept is quite similar with the traditional immunoassay and is easily accepted and understood by those who have a background in immunology. Compared with covalent immobilization, this method is relatively simple since only one polymer modification procedure, use of the first chemical, is needed before the crystal is exposed to the protein to be immobilized.

— Although there are a number of methods for biomolecule immobilization, many are deficient for one or more reasons. In general, the method of choice depends on the properties of the biomolecule to be immobilized and the desired performance of the sensor.

To achieve either the chemical modification or the protein immobilization, several coating techniques can be adopted which include dipping, dropping, and spinning. The dip-coating method relies on physical or chemical adsorption of materials to be coated onto the crystal from solution in a suitable solvent of suitable concentration. This procedure is easy to perform just by dipping the crystal into the solution of the chemical/biochemical to be coated for an indicated time. One problem encountered with this technique is the requirement for relatively large quantities of the solution, so that the whole crystal can be immersed into it. The drop-coating method is based on the application of coating material onto the surface of the crystal as a droplet of a volume of several microliters. The former technique can ensure a desired long period of interaction between the crystal surface and the solution and provide a sufficient contact between the surface and the solution. The latter one, however, has a limitation of interaction time because of the spreading and evaporation of solvent and there can be a problem of non-

uniformity of contact between the crystal surface and the solution drop. But the latter method is suitable for polymer coating since the loading of the polymer can be readily calculated from the solution concentration and droplet volume. An alternative method quite suitable for polymer coating is referred to as spin coating. In this method the polymer, dissolved in a suitable solvent, is dropped onto the crystal while it is being spun at high speed. As a result the solution spreads out to form a thin, uniform film across the surface of the crystal which, on evaporation of the solvent, leaves a polymer film over the surface of the crystal.

During the whole procedure of fabricating a Pz immunosensor, the above mentioned coating techniques are adopted individually or combined depending upon the different coating materials and different reaction conditions required.

Figure 3 is a diagram of a container which is suitable for dip-coating the crystal with a minimal amount of precious protein. It is made of microscope slides adhered by Araldite with specially designed dimensions 54 mm×12 mm×1 mm, which is suitable for dipping three crystals at the same time. By using this special container, 200 μ L of the coated protein is enough for each crystal. Under optimal protein concentration, micrograms of extracted protein is enough for coating each crystal.

In using an immunoassay and immunosensor, prior to running the samples care must be taken to prevent the non-specific adsorption of interfering proteins to the coated solid phase or fabricated sensor transducer. The presence of non-specific adsorption may result in undesired adsorption of interfering proteins when processing the sample detection. A commonly used method to prevent non-specific adsorption involves incubating of the coated surface with blocking reagents, by which the non-occupied active residues can be occupied by non-activated protein. In a traditional immunoassay bovine serum albumin, human serum albumin, casein, gelatin, detergents, and nonfat dried milk, etc., are commonly used to practice this aim (Crowther, 1995). In the present invention, appropriate blocking reagents are adopted to meet with requirements for different situations. The blocking is achieved either by dipping the coated crystal in a blocking reagent or dropping a droplet of the said blocking solution onto the coated surface. This procedure is performed after the sensing protein immobilization, so that when incubated with the detected samples any mass attachment not caused by specific immunoreaction can be prevented.

The purpose of washing is to separate bound and unbound (free) reagents. During the sensor fabrication stage, washing steps are achieved with the solvent used in the relevant coating procedure and followed by distilled water. To monitor the whole coating process, F_0 , F_1 , and F_2 are measured in a dry state. The ΔF between two successive procedures corresponds to the absolute amount of the material attached, which can be calculated on the basis of the Sauerbrey equation. The uniform frequency change of each immobilization procedure between individual crystals will lead to a uniform amount of protein binding between individual crystals, and furthermore, the ability to reproduce the sample detection can be ensured.

The washing solution used following the biomolecule immobilization and the blocking procedure is usually buffered, typically PBS (0.01-0.1 M, pH 7.4), in order to maintain isotonicity, since most antigen-antibody reactions are optimal under such conditions. Besides the preservation of activity for the immobilized protein, the other critical requirement is the stability of the protein on the sensor transducer, which affects the long term stability and sensitivity of the sensor. In the present invention the multi-washing is needed to ensure the stability of the immobilized protein (F_B' , F_B'' ). The frequency change or lack of frequency change between the multiple washing steps indicates whether the desorption occurred or not.

Figure 4 is a diagram describing the principle of the fabricated Pz sensor with an immobilized sensing protein layer for performing the detection of specific antibodies from animal body fluids. 28 refers to a Pz crystal; 30 is the coated sensing protein (antigen); 32 is the target antibody which is specific to the coated antigen; 34 is the blocking non-active protein; 36 represents other antibodies; and 38 represents other serum components. This detection procedure according to the present invention includes the following steps: 1) obtaining the resonant frequency of the coated and blocked crystal at dried state F_R ; 2) incubating the test sample solution with the reactive surface of the crystal; 3) washing away unbound material and drying the crystal; and 4) measuring the resonant frequency of the crystal F_S . The frequency change or lack thereof (before and after incubation with specimen ($F_R - F_S$)) indicates the presence or absence of the antibodies to antigens, and provides a positive/negative or YES/NO answer for the diagnostic test.

The reaction between antibodies and coated antigens depends on the distribution, time, temperature, and pH at which the incubation step takes place. The temperature for incubation is most commonly 37°C or room temperature. The time of incubation is several minutes to 1 hour.

Incubation steps in the present invention involve either dipping the coated crystal into a specimen or dropping the specimen onto the surface of the crystal and allowing the solvent to evaporate. The time and temperature required depend on the titer of each different immunoreaction system. The buffering condition, in the present invention, is controlled by PBS buffer, which maintains a pH 7.2.

The used crystal can be regenerated and reused several times in either of two ways. If a fabricated crystal is incubated with a negative sample, producing only a small signal change, it can be reused to perform another detection. On the other hand, the used crystals can be regenerated by using certain solutions to strip the coating completely and rebuilding a fresh gold surface. The regenerated crystal can be used to construct any other coating by means of new surface modification. In this sense, the crystals have no limited life.

A Pz crystal based immunosensor has been proved to be inexpensive, simple, and can perform a detection rapidly. Once a sensing layer has been immobilized on the surface of the Pz crystal, the assay time required is several minutes to 1 hour. Furthermore, this assay requires minimal technical skill, simple procedures, and no sophisticated laboratory equipment.

The present invention is further detailed in the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below are utilized.

EXAMPLE 1

The Fabrication of a Pz Sensor for the

Detection of *Salmonella enteritidis* Disease in Chickens

A) Preparation of Recombinant *Salmonella enteritidis* (SE) Antigen

Unique sequences encoding for *Salmonella* serotype *enteritidis* in chicken were identified. These allow for the specific detection of *S. enteritidis*. Nucleotides 754-1023 of a clone of a partial gene sequence of a flagellin (GenBank Accession No. Z15068) were utilized giving a 270 bp sequence (SEQ ID NO:1) encoding 90 amino acid residues (SEQ ID NO:2). The 90 aa peptide reacts specifically with sera from chickens infected with *S. enteritidis*. Chromosomal DNA from *Salmonella enteritidis* strain 13076 was used to amplify the sequence by means of polymerase chain reaction (PCR) techniques. The amplified PCR product was inserted into a bacterial expression vector next to a gene for glutathione S-transferase (GST) such

that a recombinant fusion protein (GST joined to the 90 aa peptide) was produced when the gene was expressed. This vector was cloned into bacterial host *Escherichia coli* JM 105 competent cells. A single colony of *E. coli* cells containing the appropriate recombinant plasmid was used to inoculate 1 mL of Luria-Bertani medium with 70 µg/mL of ampicillin (included for the selection of the transformed cells). After 4 hours, 200 µL of this culture was diluted 1:10 and incubated at 37°C with shaking at 250 rpm for 10 hours. This culture was then further diluted 1:10 in an appropriate flask and grown under the same conditions as previously described. When the O.D. 600 of the culture reached 0.6, IPTG (isopropyl-β-D-thiogalactopyranoside) was added to a final concentration of 2.5 mM and incubation was continued for another 4 hours. The bacterial cells were then pelleted and the cell pellet resuspended in lysis buffer (50 mM Tris pH 8, 0.3 mM NaCl, 0.5 mM EDTA, 0.5% Tween 20). The bacterial cells were then sonicated and centrifuged at 10000xg for 20 minutes. The protein was sequentially extracted from the pellet in the supernatant and in 1 M, 6 M, and 8 M urea all dissolved in lysis buffer. Protein at each step of this purification was analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and visualized by staining with Coomassie brilliant blue. Most of the recombinant protein was recovered in the supernatant and 1 M urea extraction. The recombinant protein in these fractions was then purified through an affinity column for GST using a kit available from Pharmacia Biotech. Further analysis by SDS-PAGE showed 98-99% purity of the protein. The molecular weight calculated from sequence is 9,000 and 35,000 determined by SDS gel electrophoresis. The purified and recombinantly expressed protein was characterized by Western blot with the use of yolk (extracted from chicken eggs) and negative and positive sera from naturally and experimentally infected chickens.

B) Fabrication of the SE-Pz Sensor

In the present invention three conventional protein immobilization procedures were adopted to fabricate the Pz sensor with recombinant *Salmonella enteritidis* protein layer on the surface of the crystal. It was proved that all these methods ensure the same amount of protein binding without loss of activity.

C) Immobilization Via a Self-assembled Monolayer Technique

10 MHz AT-cut mounted crystals with gold electrodes (from ICM Co. Inc., Oklahoma, USA) were cleaned with hot Piranha solution (30% H_2O_2 : H_2SO_4 (1:3)). The Piranha solution was spread on the gold surface for 5 minutes, after which the electrode surface was thoroughly
5 rinsed with distilled water. This was followed by rinsing with 95% ethanol and then with distilled water again. This procedure was repeated twice. The surface was then finally blown dry with a stream of nitrogen gas and the resonance frequency (F_0) was taken.

For covalent binding of said SE antigen, in this experiment, the surface of a gold electrode was first modified by 4-aminothiophenol (ATPh) which provides a thiol group on one
10 side and an amino group on the other side of the molecule. The spontaneous adsorption of thiol group to the gold surface ensures that the amino group faces towards the interface and works as a functional residue to which another amino group from a protein can be immobilized by means of a cross-linking reagent. This said immobilization was achieved by dipping the freshly cleaned crystal immediately into 20 mM of ATPh (the first chemical) in dimethylsulfoxide (DMSO)
15 overnight at room temperature. After washing with distilled water and air drying, the obtained amino groups were further activated by dipping the modified crystal in 2.5% glutaraldehyde (GA) in PBS (the second chemical) for 1 hour. After washing with PBS buffer and rinsing with distilled water, incubation with protein was performed.

Application of a droplet of protein onto the coated crystal is the most commonly used
20 technique to fabricate a sensing layer, particularly in antibody coating. In this experiment, this technique was first investigated. This involved applying 5 μL each of concentrated SE protein solution (500 $\mu\text{g/mL}$) on each side of the activated crystal and incubating at 37°C until the solvent evaporated completely. Unfortunately, however, this method failed to ensure that all the coated crystal would have the desired amount of protein to be immobilized (corresponding to a
25 certain frequency change). The reasons may be the limited incubation time this method offered and the content of 0.1% SDS in the protein solution which is used in purifying the recombinant protein. To overcome these problems, an alternative dipping coating technique was developed by which the modified crystals were dipped into a diluted SE PBS solution (25 $\mu\text{g/mL}$) and incubated for a desired period of time (1-2 hours) at 37°C. This technique is based on the design
30 and use of a homemade microcontainer, which is of the size of 54 mm x 12 mm x 1 mm, capacity

of 648 microliters. This special design allows three pieces of crystal to be dipped simultaneously, and typically, 5 μg of recombinant protein is enough for each crystal.

This method is found to be more suitable for recombinant protein coating, for it not only ensures a sufficiently long period of incubation time but also reduces the amount of protein needed. Moreover a longer incubation time allows the use of lower concentrations of coated protein. In this example, use of an SE concentration up to 25 $\mu\text{g/mL}$, the binding amounts correspond to saturation of the surface, i.e., the frequency stops changing. Furthermore, diluted protein results in a minimal amount of the anionic detergent SDS and prevention of the protein immobilization is reduced. Besides, this dipping method is beneficial in reducing the variation of the amount of protein binding to individually coated crystals since it ensures a sufficient and uniform contact between crystal and the protein solution. The binding amount of SE protein by drop- and dip-coating technique are compared in Table 1.1.

Table 1.1

SE binding amount corresponding to frequency change*

Method	Dropping	Dipping
ΔF (Hz)	165.3 \pm 33.2	256 \pm 23.3
Binding capacity (nmol/side)	0.0021	0.0032

* Average from at least 8 crystals

D) Immobilization Via Silanization Method

Another type of coating procedure is based on the silanization method. The crystals were cleaned in 1.2 N NaOH for 20 minutes followed by 5 minutes in 1.2 N HCl. The crystals were then rinsed with distilled water and air-dried. Subsequently several microliters of concentrated HCl were applied on the surface for 1-2 minutes. Finally, the crystals were rinsed with distilled water and ethanol.

The clean crystals were first modified by dipping in 5% γ -aminopropyltriethoxysilane (γ -ATPES) in acetone for 1 hour. After washing with acetone and distilled water (F_1), the following procedures are the same as for the APTs method, which consists of further activation by GA (F_2) and finally incubation with 25 $\mu\text{g/mL}$ of recombinant SE protein by dipping (F_B). Multiple washing steps were followed to ensure the stability of the coating (F_B' , F_B'').

E) Immobilization Via Polystyrene Method

The crystals were cleaned by the alternating base and acid method, as described previously. Polystyrene beads were dissolved in toluene into which cleaned crystals were dipped for 30 minutes at room temperature to form a polymer film by physical adsorption. After rinsing with ethanol and distilled water (F_1) the crystals with polymer film were dipped into recombinant SE protein in coating buffer for an appropriate period of time (F_B).

The thickness of polystyrene film depends on the concentration of the polymer solution. In this case 3 mg/mL was adopted, and the amount of polymer coating corresponding to the frequency change was 1196 ± 125 Hz. Although 9 mg/mL of polymer provided a thicker polymer coating corresponding to a frequency change of 4919 ± 325 Hz, the amount of protein coating no longer increased. This indicated that 3 mg/mL of polymer provided a saturated polymer coating and the coating covered the whole area of the crystal.

The adsorption of protein onto plastic is based on hydrophobic interactions. The rate of the interaction depends on the concentration of the protein, coating pH, temperature, and time of incubation. In this case the optimal coating procedure was dipping the crystal in SE solution (25 μ g/mL in 50 mM carbonate coating buffer, pH 9.6) at 37°C for 1 hour. It is indicated that the concentration of SE up to 25 μ g/mL resulted in the saturation amount of binding corresponding to a frequency change of 240 ± 19.9 (Table 1.2).

Table 1.2

Frequency change caused by binding of SE protein under different concentrations

Conc. (μ g/mL)	30.0	25.0	12.5	10.0	6.0
ΔF (Hz)	232	240	171	140	55

During the whole coating process, $F_0 - F_B$ were taken in order to monitor the reaction procedures. It is proved that the three immobilization methods ensure almost the same amount of SE binding (Table 1.3) without loss in activity. These coating methods were stable, as there was no frequency change during the washing procedures. Under the optimal coating condition, 5 μ g of the said protein are enough for the fabrication of one Pz crystal.

Table 1.3

Procedures of SE binding by different methods

Steps	Method		
	<u>ATPh</u>	<u>γ-APTES</u>	<u>Polystyrene</u>
		ΔF (Hz)	
First Chemical	1063 \pm 12.8	545 \pm 58.6	1196 \pm 125
Second Chemical	171 \pm 19.1	273 \pm 221	NIL
SE protein	256 \pm 18.3	232 \pm 22.3	240 \pm 23.2

In the present invention, a polystyrene-coating method was first recommended as it offers a relatively simple concept and reduction of immobilization time. By means of the said coating process a large quantity of Pz crystals with SE protein coating layer were fabricated to conduct the test for SE specific antibody from chicken serum samples or egg yolk.

To avoid non-specific adsorption, the SE protein coated crystals were incubated with BSA by dropping 5 μ L of 5% BSA on each side of the crystal or dipping the crystals in 1% BSA solution at 37°C for half an hour. After washing and drying the said crystals were kept at 4°C or refrigerated.

For SE detection the polystyrene method was selected as the best method and in the following sections (F) and (G) of this Example the Pz crystals used were prepared with the polystyrene coating method. SE protein fixing on a polystyrene modified surface is based on a physical adsorption. It was found that a polystyrene modified electrode surface results in a low activity for binding interfering proteins and consequently nonspecific binding is greatly reduced. The binding of SE to the polystyrene film is due to electrostatic interaction which is achieved by a long (overnight) incubation. A short incubation (5-10 minutes) with the serum sample allows only specific antibody binding to the coated antigen.

F) Detection of SE Antibodies from Chicken Sera

The fabricated crystals were taken from the freezer and allowed to equilibrate to room temperature. The resonant frequency was measured as F_R . Sample used in this detection was chicken sera. Diluted serum samples reduced the background caused by interfering protein, but also caused a loss of sensitivity due to the lower antibody concentration. In this example, dilution of serum samples fifty-fold (1:50) with PBS buffer was found to be the best compromise between

the requirements of sensitivity on the one hand and handling of interfering binding on the other hand. Under the optimal dilution, 10 μ L of diluted serum sample was placed onto each of the two sides of the crystal and covered the whole area of the electrode at room temperature for about 20 minutes. After washing and drying of the said crystal, resonant frequency values were determined as F_s . $F_R - F_s$ corresponds to the mass adsorption caused by detected serum sample.

A total of 47 chicken sera were involved. Six control negative and 6 control positive sera were used to identify the performance of the fabricated sensor. The results are shown in Figure 5. The frequency change caused by positive and negative samples is obviously different and provides a YES or NO diagnostic result. The cut-off value was set as the average signal of the six negative controls plus three times SD which gave a cutoff threshold of 176.7 Hz in this case.

Another 35 unknown sera were assayed using an SE-Pz sensor (Figure 6) and the results were compared to traditional immunoassay results. For an SE-Pz sensor, the presence or absence of antibody to SE is determined by a frequency change of the crystal before and after incubation with serum specimen. If the ΔF ($F_R - F_s$) is less than the cutoff threshold, 176.7 Hz in this case, the sample is classified as negative for SE antibodies, and if the ΔF is greater than or equal to the cutoff threshold, the sample is classified as positive for SE antibodies. The positive control serum (serum 0) produced a highly positive signal. Six samples out of 35 were stronger than or as strong as the positive control serum. Another 11 samples appeared as positives and the remaining 18 were negative. These results all agree, except from serum 33, with a Western blot assay and the commercially available IDEXX SE Antibody Test Kit. Table 1.4 is a 2 \times 2

Table 1.4
Summary and comparison of SE-Pz sensor and traditional immunoassay

Western blot/IDEXX ELISA confirmed			
	Positive	Negative	Total
SE-Pz sensor positive	16	1	17
SE-Pz sensor negative	0	18	18
Total	16	19	
SE-Pz sensor positive	a	b	a+b
SE-Pz sensor negative	c	d	c+d
Total	a+c	b+d	

Sensitivity = $a/(a+c)$; Specificity = $d/(b+d)$; Concordance = $(a+d)/(a+b+c+d)$

contingency Table, by which the comparison of SE-Pz sensor with the two traditional immunoassay are made. The Pz sensor and traditional immunoassay result concordance was 96%, and the relative sensitivity and specificity were 100% and 95%, respectively.

5 G) Detection of SE antibodies from chicken yolk

In this example, the detected sample type is egg yolk. Dilutions from 1:1 to 1:10 were tested. It was found that a 1:5 dilution with PBS buffer was optimal for the requirements of sensitivity and handling of the interfering binding. Under the optimal dilution, 10 μ L of diluted egg yolk sample were added onto both sides of the crystal and covered the whole area of the
10 electrode in a 37°C incubator for about 30 minutes. After washing and drying the said crystal, a resonant frequency value was determined as F_s . $F_R - F_s$ corresponds to the mass adsorption caused by detected samples. A total of 19 known egg yolks from experimentally infected or uninfected chickens were detected by an SE-Pz sensor. The results are shown in Figure 7. The cut-off value was defined as the average of the negative samples plus three times the standard
15 deviation.

— EXAMPLE 2

Fabrication of a Pz sensor for the Detection of Porcine

Reproductive and Respiratory Syndrome Virus Disease in Pigs

20 A) Preparation of Recombinant Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Antigen

Unique sequences encoding for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in pigs were identified. PRRSV has eight Open Reading Frames (ORFs) in its genome: 1a, 1b, 2, 3, 4, 5, 6, and 7. A PRRSV strain was used for amplification of viral ORFs 5 and 7 by
25 PCR and cloned into bacterial host *Escherichia coli* JM 105 competent cells. The ORF 5 DNA sequence is shown as SEQ ID NO:3 and the ORF 5 protein sequence is given as SEQ ID NO:4. The subsequent recombinant expression process and purification procedure were nearly identical to that for the SE antigen described in Example 1. Viral protein products from ORFs 5 and 7 were recovered in the 8 M urea extraction step. The 8 M urea fraction was purified by excision
30 of the band from a preparative SDS-PAGE. The purified and recombinantly expressed protein were 98-99% pure and were characterized by a Western blot with the use of positive and negative

sera from naturally and experimentally infected pigs. The molecular weight calculated from sequence is 9,000, and 41,000 kD determined by SDS gel electrophoresis.

B) Fabrication of a Pz Sensor with PRRSV ORF 5 Antigen Layer (PRRS-ORF 5-Pz Sensor)

5 In this example, recombinant PRRSV-ORF-5 protein was used as sensing antigen. To fabricate the Pz sensor with a PRRSV-ORF-5 protein layer, covalent and non-covalent immobilization methods were adopted as described in Example 1. Although each method ensured a sufficient amount of protein binding corresponding to certain frequency changes, further experiments indicated that covalent binding is not suitable to distinguish the positive and
10 negative serum samples. Two problems were encountered. The relatively strong background contributed by the negative control and the weak frequency change when incubated with the positive control. The former problem may indicate that the nonspecific adsorption residue of the coated surface still exists as the result of the interfering proteins, the serum component, adsorbed on it. The latter problem may result from loss of activity of the coated PRRSV protein and as a
15 result the immuno-reactions between detected antibody and the coated PRRSV protein were prevented. To overcome these two problems and obtain a clear distinction between positive and negative signals, the following efforts were made. First, appropriate blocking reagents, such as PBS, dried milk, gelatin and casein buffer, were used to incubate with PRRSV coated crystal before contacting the coated crystal with serum samples. Second, to increase the frequency
20 change signal caused by the positive control serum, the serum incubation conditions were modified including the time, temperature, and serum dilution. All these efforts were ineffective in improving the performance of the sensor.

 Fortunately, the non-covalent binding of PRRSV protein directly onto the surface of the crystal is quite reasonable for fabrication of the Pz sensor with PRRSV layer.

25 There is a strong and irreversible adsorption of protein on a gold electrode due to the hydrophobic and thiol-gold interaction between protein molecules and gold surface. To immobilize PRRSV protein onto the surface of the crystal, the thoroughly cleaned crystals (F_0) were dipped into PRRSV protein solution overnight at room temperature. To avoid the evaporation of the solution, the homemade micro-container with dipping crystal was kept in a
30 box at high humidity. After washing with distilled water the coated crystals were air-dried (F_B). Casein buffer, which contains 0.5% casein, 0.2% Tween 20 in PBS buffer, was incubated with

the crystal at room temperature for 1 hour. This was followed by washing and drying (F_R). $F_0 - F_B$ corresponds to the amount of protein binding, and $F_B - F_R$ relates to the adsorption of the block protein.

5 The rate and extent of protein coating on a gold surface depend on: 1) the diffusion coefficient of the coated molecule; 2) the ratio of the surface area being coated to the volume of coating solution; 3) the concentration of the substance being adsorbed; 4) the temperature; and 5) the length of time of adsorption. All these factors are linked and the most important is to determine the optimal antigen concentration for coating in each system. To ensure high sensitivity of the fabricated sensor the coating protein needs to saturate available sites on the surface of the crystal on the one hand. On the other hand care must be taken to assess effects of binding proteins at different concentration, since the actual density of binding may affect results. High-density binding of antigen may not allow antibody to bind because of steric inhibition (the antigen molecules being too closely packed).

10 The concentration range of PRRSV protein used in this Example was 5-50 $\mu\text{g/mL}$. In this range the protein binding amount corresponded to a frequency change of 140-800 Hz. After blocking the coated crystals (F_R), a real PRRSV-positive pig serum was incubated with them (F_S) and the sensitivity of the sensors with different PRRSV protein binding capacities was monitored (Figure 8). It was observed that PRRSV binding amount at the range of 196.4-312.5 ng/double side, corresponding to a frequency change of 220-350 Hz, was the most sensitive, with the ΔF ($F_R - F_S$) caused by the positive control being 260-320 Hz.

20 To obtain 220-350 Hz of PRRSV binding, 25 $\mu\text{g/mL}$ of PRRSV solution was used as the optimal concentration. Under this condition, a large quantity of crystals were coated. The amounts of protein binding to ten crystals are shown in Table 2.1. The highly uniform amount of PRRSV protein binding for each fabricated crystal is the basis of high sensor-to-sensor reproducibility. This physical adsorption method was used for the experiments described below in sections C-F of this Example.

25

Table 2.1

ORF 5 PRRSV protein binding amount

No.	ΔF caused by PRRSV binding (Hz)	Binding capacity (ng/side)	Binding capacity (nmol/side)
1	250	112.8	0.0028
2	330	148.8	0.0036
3	285	128.5	0.0031
4	325	146.6	0.0036
5	260	117.3	0.0029
6	310	139.8	0.0034
7	360	162.4	0.0040
8	265	119.5	0.0029
9	280	126.3	0.0031
10	300	135.3	0.0033
Average \pm SD	296.5 \pm 35.0	133.7 \pm 15.8	0.0033 \pm 0.00038

C) Sample Test Protocol

The coated and blocked crystals were kept at 4°C. The coated and blocked crystals were removed from the refrigerator and allowed to reach room temperature. The resonant frequency was measured as F_R . The samples used in this detection were pig serum samples. In this Example, diluting serum samples five-fold (1:5) with PBS buffer was found to be the best compromise between the requirements of sensitivity and handling of interfering binding. Under the optimal dilution, 10 μ L of diluted serum sample were added on each side of the crystal and the whole area of the electrode was covered at room temperature for 10 minutes (it was found that a 10 minute sample incubation is optimal). After washing and drying the said crystal, resonant frequency values were determined as F_S . $F_R - F_S$ corresponds to the mass adsorption caused by the detected serum samples.

A total of 41 pig sera were included in this Example. Figure 9 shows the summarized measurement results in a column graph. Of these samples 12 sera (group A) and 14 pig sera (group B) are negative controls and positive controls, respectively, which were employed to determine the performance of the sensors. 12 true PRRSV-negative reference sera (group A) had normally distributed $F_R - F_S$ values ranging from 0 to 60, with a mean value of 30.0 \pm 20.9 Hz (Table 2.2). The cutoff threshold was set as the average frequency shift of 12 negative controls plus three times the standard deviation. Another 15 pig sera (group C) were unknown sera and

were used to compare the sensitivity and specificity of the sensor with traditional Western blot and commercially provided ELISA results. The presence or absence of antibody to PRRSV is determined by a frequency change of the crystal before and after incubation with the serum specimen ($F_R - F_S$). If the ΔF is less than cutoff threshold, the sample is classified as negative for PRRSV antibodies, and if the ΔF is greater than or equal to cutoff threshold, the sample is classified as positive for PRRSV antibodies. 8 samples out of the 15 in group C were positive and the rest were negative. These results all agreed well with the IDEXX PRRS Antibody Test Kit or Western blot assay.

Table 2.2
Distribution of ORF 5 PRRS Pz sensor
frequency change value for real negative pig serum samples

No.	ΔF (Hz)
1	60
2	5
3	52
4	32
5	10
6	40
7	7
8	2
9	36
10	50
11	9
12	55
Average \pm SD	30.0 \pm 20.1
Cutoff threshold (Average + 3 SD)	90.2

D) Cross Comparison between IDEXX ELISA

Several real pig sera results obtained by an ORF 5 PRRSV Pz sensor were cross-compared with the results of the commercially available IDEXX PRRS ELISA TEST KIT (Table 2.3). The IDEXX PRRS ELISA procedures were performed using the standard protocols, by which the presence or absence of antibody to PRRSV is determined by calculating the S/P ratio of each sample. If the S/P ratio is less than 0.4, the sample is classified as negative for PRRSV antibodies, and if the S/P ratio is greater than or equal to 0.4, the sample is classified as positive for PRRSV antibodies.

Table 2.3

Cross comparison between PRRS-ORF 5-Pz sensor and IDEXX ELISA

		<u>PRRSV Pz sensor</u>		<u>IDEXX PRRS ELISA</u>	
		ΔF (Hz)	Normalized signal *	S/P ratio	Normalized Signal*
5	Cut-off threshold	90.2		0.40	
	1(-)	0	0	0.10	0.25
	Pig 2(-)	10	0.11	0.17	0.41
	Serum 3(-)	35	0.39	0.24	0.60
	Samples 4 Weak (+)	155	1.72	0.73	1.83
10	5 Weak (+)	140	1.55	0.63	1.58
	6(+)	310	3.44	2.0	5.00
	7(+)	250	2.78	2.1	5.25

The normalized signal of each sample is defined as the ratio of the frequency change of the sample, ΔF_{sample} or $(S/P)_{\text{sample}}$, to cutoff threshold frequency. Each serum in Table 2.3 with a measurement normalized value larger than 1 can be classified as a positive specimen. Serum samples 1-3 were identified by a Pz sensor as negative with a normalized signal range from 0-0.39, whereas the normalized signal from the IDEXX ELISA was in the range of 0.25-0.60. Serum samples 6 and 7 were strong positives with a normalized signal from the Pz sensor of 2.8-3.4, and the IDEXX ELISA gave a normalized signal of 5.00-5.25. Serum specimen Nos. 4 and 5 were identified as weakly positive. The normalized signals for both the PRRSV Pz sensor and the commercial IDEXX ELISA were only a little bit higher than 1.

E) Reproducibility of the ORF 5 PRRSV Pz Sensor

To monitor the reproducibility of frequency change from sensor to sensor, several sera samples were detected multiple times with different fabricated sensors (Table 2.4). The standard deviation was in the range of 5.0-15.0%, which was comparable with IDEXX results and were acceptable.

Table 2.4

Parallel detection of serum samples by different Pz crystals

Sample							
ΔF (Hz)		1 (-)	2(-)	3 (Weak +)	4 (+)	5(+)	6(+)
5	Times						
	1	90	10	140	310	225	295
	2	55	20	115	250	195	310
	3	60	5	--	320	250	--
	4	--	--	--	240	--	--
10	Ave. \pm SD	67.8 \pm 9.9	15.3 \pm 2.3	127.5 \pm 17.7	275.5 \pm 23.3	223.2 \pm 27.5	302.5 \pm 17.5
	RSD (%)	14.6	15.0	13.8	8.5	12.3	5.3

F. Reusability of the sensors

The reusability here refers to the case in which a fabricated crystal was used to detect a negative serum first, and it could be reused to perform another assay. Four fabricated crystals (1-4) were employed to detect two negative control sera, and two positive control sera in different order. The result is shown in Figure 10. Crystal 1 was incubated with negative control 1 first, with the resulting signal, ΔF , being 36 Hz. Crystal 1 was then incubated with negative control 2 and produced a 50 Hz frequency change. Furthermore, this twice-used crystal was then incubated with a positive control and the produced signal was 225 Hz. Crystal 2 was used as a reference, by which the same positive control was detected directly, and produced a 250 Hz signal. Another two crystals were used to perform a similar experiment. Positive control 2 was detected by a once-used crystal and directly by a new crystal. The produced frequency signals from the two tests were very close to each other, and the SD was within the proposed SD, 15%. This indicated that fabricated crystals can be reused at least 3 times without obvious loss of sensitivity.

Example 3Regeneration of Used Crystals

After a positive sample assay, the regeneration of fabricated crystals can be performed by a pH-shift. Soaking the used crystal for 30 minutes in buffered boric acid/KCl-NaOH, pH 11.0 (50 mL of 0.025 M borax + 22.7 mL 0.1 M NaOH) can remove the antibody from the immunocomplex. After washing with distilled water and PBS buffer the crystal can be used for

another assay. Figures 11A-B show the sensitivity of a regenerated PRRSV-Pz sensor (Figure 11A) and a regenerated SE-Pz sensor (Figure 11B). About 3-4 assays can be performed before irreversible loss of activity occurred.

5 Dichromate acid (10 g potassium dichromate dissolved in 30 mL hot H₂O, let cool, add 70 mL concentrated H₂SO₄) washing solution was found to be the best way to strip the whole coating from a fabricated sensor surface. It is suitable for almost all surface conditions. For example, a thiol compound modified surface has a strong linkage between gold and a sulfur atom. Treating the said surface by dropping 10 µL of dichromate acid solution for more than 15 minutes, followed by rinsing with distilled water can make the frequency return to the original
10 base line F₀, and any new surface modification is permissible on the newly built gold surface. Figure 12 shows the comparison of regeneration ability of dichromate acid solution and hot Piranha for the thiol compound treated surface. Recombinant PRRSV protein immobilization directly on gold is proved to be rather stable. The regeneration for a PRRSV adsorbed gold surface involves incubation of the surface with dichromic acid for 15 minutes.

15 The interaction of γ-APTES on gold is based on three gold and oxygen linkages. Regeneration of a γ-APTES treated crystal can be achieved by washing for a long length of time. Figure 13 shows the regeneration ability of dichromate acid washing solution for APTh and γ-APTES treated crystals.

20 While the invention has been disclosed in this patent application by reference to the details of preferred embodiments of the invention, it is to be understood that the disclosure is intended in an illustrative rather than in a limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.

25

LIST OF REFERENCES

- Breckenstein S And Shay M (1985). *Electronchim. Acta* 30:1295.
- Crowther JR (1995). *Methods in Molecular Biology* 42:1-218.
- Franks F (1993). *Protein Biotechnology*, p. 467 (Humana Press, Totowa, New Jersey).
- 5 Heberling RL and Kalter SS (1986). *J. Clin. Microbiol.* 23:109-113.
- Horisberger M and Vauthey M (1984). *Histochemistry* 80:13-18.
- Karube I and Suzuki M (1986). *Biosensors* 2:343-362.
- Shons A, et al. (1972). *J. Biomed. Mater. Res.* 6:565-570.
- Thorns CJ, et al. (1996). *J. Clin. Microbiol.* 34:792-797.
- 10 Williams RA and Blanch HW (1994). *Biosensors & Bioelectronics* 9:159-167.
- Singapore Patent Application No. 9801211-5
- U.S. Patent No. 4,236,893
- U.S. Patent No. 4,242,096
- U.S. Patent No. 4,314,821
- 15 U.S. Patent No. 4,689,295
- U.S. Patent No. 4,735,906
- U.S. Patent No. 5,212,065
- U.S. Patent No. 5,236,824
- U.S. Patent No. 5,554,340
- 20 U.S. Patent No. 5,565,365
- U.S. Patent No. 5,630,924
- U.S. Patent No. 5,695,928

CLAIMS

1. A method for performing an immunodiagnostic test for the presence of an infectious agent in an organism comprising:
 - a) immobilizing i) an antigen from said infectious agent or ii) an antibody specific for an antigen from said infectious agent on a piezoelectric (Pz) crystal;
 - b) measuring a resonant frequency of said crystal following step (a);
 - c) contacting said crystal with a biological specimen from said organism to be tested;
 - d) measuring a resonant frequency of said crystal following step (c);
 - e) comparing the resonant frequency measured in step (b) with the resonant frequency measured in step (d) wherein if the difference between the two frequencies is equal to or greater than a cut-off threshold value then said biological specimen is positive for the presence of said infectious agent.
2. The method of claim 1 wherein said antigen is a recombinant antigen.
3. The method of claim 1 wherein said infectious agent is a bacterium or a virus.
4. The method of claim 1 wherein following step (a) said crystal is contacted with a blocking reagent.
5. The method of claim 1 wherein said Pz crystal comprises a 0.1 to 1000 MHz AT-cut crystalline quartz crystal.
6. The method of claim 5 wherein said Pz crystal further comprises silver or gold electrodes.
7. The method of claim 5 wherein said Pz crystal further comprises an oscillator circuit capable of electrically stimulating said Pz crystal to oscillate at its inherent resonant frequency.
8. The method of claim 1 wherein said resonant frequencies are measured using a universal counter.

9. The method of claim 1 wherein said antigen is a transmembrane envelope protein.
10. The method of claim 9 wherein said transmembrane envelope protein is recombinantly produced as a fusion protein comprising glutathione S-transferase.
11. The method of claim 1 wherein said immobilizing is performed by a method selected from the group consisting of 1) physical adsorption onto a metal or polystyrene modified crystal and 2) covalent binding onto a polymer, silane or thiol compound treated crystal.
12. The method of claim 11 wherein said immobilizing is performed by dipping said Pz crystal into a solution of said antigen.
13. The method of claim 1 wherein said biological specimen is diluted prior to said contacting.
14. The method of claim 4 further comprising washing steps following step (a), the step of blocking, and step (c) wherein said washing is with a physiological buffer comprising a detergent.
15. The method of claim 14 wherein said physiological buffer is a phosphate buffered saline.
16. The method according to claim 4 wherein said blocking reagent is a non-active protein.
17. The method according to claim 16 wherein said blocking agent is bovine serum albumin or casein buffer.
18. The method according to claim 4 wherein said blocking reagent is applied by a dip technique or a drop technique.
19. The method of claim 1 wherein said contacting with a biological specimen is performed in a liquid phase or in a vapor phase.

33

20. The method according to claim 1 wherein said cut-off threshold is defined as the mean value of negative controls plus three times the standard deviation.
21. The method of claim 1 wherein said Pz crystal was previously used in a test which was negative for said infectious agent.
22. The method of claim 1 wherein said antigen comprises a peptide of SEQ ID NO:2.
23. The method of claim 1 wherein said antigen comprises ORF 5 of PRRSV.
24. A method of regenerating a used Pz crystal coated with i) a bound antigen or ii) a bound antibody by washing with a buffer containing boric acid/KCl-NaOH to remove any protein bound to said antigen or antibody while not removing said antigen or antibody thereby allowing said Pz crystal with bound antigen or antibody to be reused.
25. A method of regenerating a used Pz crystal by washing with dichromate acid thereby removing any bound protein and any bound antigen to produce a clean crystal to which new antigen can be bound.
26. A method of coating a Pz crystal with an antigen or antibody comprising dipping said crystal in a solution of said antigen or said antibody.
27. A diagnostic kit comprising a Pz crystal coated with a recombinant antigen or an antibody.
28. The diagnostic kit of claim 27 wherein said recombinant antigen comprises a protein of SEQ ID NO:2.
29. The diagnostic kit of claim 27 wherein said recombinant antigen comprises ORF 5 of PRRSV.

1/13




FIGURE 1

2 / 13




FIGURE 2




FIGURE 3

4/13




FIGURE 4

5/13




FIGURE 5

6/13




FIGURE 6

7/13




FIGURE 7

8/13




FIGURE 8

9/13





FIGURE 9

10/13



Negative control 1, ■ Negative control 2, ▨ Positive control 1, ▩ Positive control 2

FIGURE 10

11/13




FIGURE 11A




FIGURE 11B

12/13




FIGURE 12

13/13




FIGURE 13

SEQUENCE LISTING

<110> Li, Sam Fong Yau
 Su, Xiaodi
 Kwang, Jimmy
 Low, Sharon
 Liu, Wei
 Institute of Molecular Agrobiology

<120> A NOVEL IMMUNO-DIAGNOSTIC TEST METHOD FOR VETERINARY
 DISEASE

<130> 2577-118

<140> Not yet assigned

<141> 1999-06-03

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 270

<212> DNA

<213> Salmonella enteritidis

<220>

<221> CDS

<222> (1)..(270)

<400> 1

tct act gct ggt acc gct gaa gcc aaa gcg ata gct ggt gcc att aaa	48
Ser Thr Ala Gly Thr Ala Glu Ala Lys Ala Ile Ala Gly Ala Ile Lys	
1 5 10 15	
ggt ggt aag gaa gga gat acc ttt gat tat aaa ggc gtg act ttt act	96
Gly Gly Lys Glu Gly Asp Thr Phe Asp Tyr Lys Gly Val Thr Phe Thr	
20 25 30	
att gat aca aaa act ggt gat gac ggt aat ggt aag gtt tct act acc	144
Ile Asp Thr Lys Thr Gly Asp Asp Gly Asn Gly Lys Val Ser Thr Thr	
35 40 45	
atc aat ggt gaa aaa gtt acg tta act gtc gct gat att gcc act ggc	192
Ile Asn Gly Glu Lys Val Thr Leu Thr Val Ala Asp Ile Ala Thr Gly	
50 55 60	
gcg acg gat gtt aat gct gct acc tta caa tca agc aaa aat gtt tat	240
Ala Thr Asp Val Asn Ala Ala Thr Leu Gln Ser Ser Lys Asn Val Tyr	
65 70 75 80	
aca tct gta gtg aac ggt cag ttt act ttt	270
Thr Ser Val Val Asn Gly Gln Phe Thr Phe	
85 90	

<210> 2

<211> 90

<212> PRT

<213> Salmonella enteritidis

SUBSTITUTE SHEET (RULE 26)

<400> 2

Ser Thr Ala Gly Thr Ala Glu Ala Lys Ala Ile Ala Gly Ala Ile Lys
 1 5 10 15

Gly Gly Lys Glu Gly Asp Thr Phe Asp Tyr Lys Gly Val Thr Phe Thr
 20 25 30

Ile Asp Thr Lys Thr Gly Asp Asp Gly Asn Gly Lys Val Ser Thr Thr
 35 40 45

Ile Asn Gly Glu Lys Val Thr Leu Thr Val Ala Asp Ile Ala Thr Gly
 50 55 60

Ala Thr Asp Val Asn Ala Ala Thr Leu Gln Ser Ser Lys Asn Val Tyr
 65 70 75 80

Thr Ser Val Val Asn Gly Gln Phe Thr Phe
 85 90

<210> 3

<211> 630

<212> DNA

<213> Porcine reproductive and respiratory syndrome virus

<220>

<221> CDS

<222> (1)..(600)

<400> 3

atg ttg ggg aaa tgc ttg acc gtg ggc tgt tgc tcg cga ttg ctt tct 48
 Met Leu Gly Lys Cys Leu Thr Val Gly Cys Cys Ser Arg Leu Leu Ser
 1 5 10 15

ttg tgg tgt atc gtg ccg ttc tgt ttt gct gtg ctc gcc gac gcc cac 96
 Leu Trp Cys Ile Val Pro Phe Cys Phe Ala Val Leu Ala Asp Ala His
 20 25 30

agc agc agc agc tct cat ctg caa ttc att tac aac ttg acg cta tgt 144
 Ser Ser Ser Ser Ser His Leu Gln Phe Ile Tyr Asn Leu Thr Leu Cys
 35 40 45

gag ctg aat ggc aca gat tgg cta gct gat aga ttt gat tgg gca gtg 192
 Glu Leu Asn Gly Thr Asp Trp Leu Ala Asp Arg Phe Asp Trp Ala Val
 50 55 60

gag agc ttt gtc atc ttt cct gtt ttg act cac att gtc tcc tat ggt 240
 Glu Ser Phe Val Ile Phe Pro Val Leu Thr His Ile Val Ser Tyr Gly
 65 70 75 80

gcc ctc act acc agc cat ttc ctt gac aca att gct tta gtc act gtg 288
 Ala Leu Thr Thr Ser His Phe Leu Asp Thr Ile Ala Leu Val Thr Val
 85 90 95

tct acc gcc ggg ttt gtt cac ggg cgg tat gtc ctg agt agc atc tac 336
 Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Leu Ser Ser Ile Tyr
 100 105 110

gcg gtc tgt gcc ctg gct gcg ttg act tgc ttc gtc att agg ttt gta 384
 Ala Val Cys Ala Leu Ala Ala Leu Thr Cys Phe Val Ile Arg Phe Val
 115 120 125

3

```

aag aat tgc atg tcc tgg cgc tac tca tgt act aga tat acc aac ttt 432
Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
130 135 140

ctt ctg gac act aag ggc aga ctc tat cgt tgg cgg tcg cct gtc att 480
Leu Leu Asp Thr Lys Gly Arg Leu Tyr Arg Trp Arg Ser Pro Val Ile
145 150 155 160

ata gag aag agg ggc aaa gtt gag gtc gaa ggt cat ctg atc gat ctc 528
Ile Glu Lys Arg Gly Lys Val Glu Val Glu Gly His Leu Ile Asp Leu
165 170 175

aaa aga gtt gtg ctt gat ggt tcc gtg gca acc cct ata acc aga gtt 576
Lys Arg Val Val Leu Asp Gly Ser Val Ala Thr Pro Ile Thr Arg Val
180 185 190

tca gcg gaa caa tgg ggt cgt cat tagatgactt ctgtcatgat agcacggctc 630
Ser Ala Glu Gln Trp Gly Arg His
195 200

```

<210> 4

<211> 200

<212> PRT

<213> Porcine reproductive and respiratory syndrome virus

<400> 4

```

Met Leu Gly Lys Cys Leu Thr Val Gly Cys Cys Ser Arg Leu Leu Ser
1 5 10 15

Leu Trp Cys Ile Val Pro Phe Cys Phe Ala Val Leu Ala Asp Ala His
20 25 30

Ser Ser Ser Ser Ser His Leu Gln Phe Ile Tyr Asn Leu Thr Leu Cys
35 40 45

Glu Leu Asn Gly Thr Asp Trp Leu Ala Asp Arg Phe Asp Trp Ala Val
50 55 60

Glu Ser Phe Val Ile Phe Pro Val Leu Thr His Ile Val Ser Tyr Gly
65 70 75 80

Ala Leu Thr Thr Ser His Phe Leu Asp Thr Ile Ala Leu Val Thr Val
85 90 95

Ser Thr Ala Gly Phe Val His Gly Arg Tyr Val Leu Ser Ser Ile Tyr
100 105 110

Ala Val Cys Ala Leu Ala Ala Leu Thr Cys Phe Val Ile Arg Phe Val
115 120 125

Lys Asn Cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe
130 135 140

Leu Leu Asp Thr Lys Gly Arg Leu Tyr Arg Trp Arg Ser Pro Val Ile
145 150 155 160

Ile Glu Lys Arg Gly Lys Val Glu Val Glu Gly His Leu Ile Asp Leu
165 170 175

Lys Arg Val Val Leu Asp Gly Ser Val Ala Thr Pro Ile Thr Arg Val
180 185 190

```

SUBSTITUTE SHEET (RULE 26)

4

Ser	Ala	Glu	Gln	Trp	Gly	Arg	His
		195					200

SUBSTITUTE SHEET (RULE 26)